NCT01382368Unknown4 期
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- VO2 Peak
研究概览
简要总结
- Pulmonary diseases are increasingly important causes of morbidity and mortality in the modern world.
- Sildenafil, an orally administered a phosphodiesterase type 5 (PDE-5) inhibitor, targets the nitric oxide (NO) pathway. The drug was first approved for the treatment of Pulmonary Arterial Hypertension (PAH) in 2005.
- The aim of the suggested study is to examine the acute effect of oral intake of sildenafil on exercise tolerance and functional capacity in Chronic Obstructive Pulmonary Disease (COPD), Idiopathic pulmonary fibrosis (IPF) and post Pneumonectomy patients.
- The investigators hypothesize that oral ingestion of sildenafil prior the exercise may enhance exercise tolerance and improve function in COPD, IPF and post Pneumonectomy patients.
- Patients and Methods:
Sixty chronic lung disease patients males and females (aged 30 to 90 years) 20 COPD (GOLD III-IV) [9, 39] , 20 IPF and 20 post Pneumonectomy patients will be recruit to this study.
- All subjects will carried out two maximal cardiopulmonary exercise tests (CPET) on bicycle ergometer in different days; 60 min after intake of placebo and 60 min after intake of 100 mg sildenafil (Pfizer, Sandwich, UK), in random order.
- In first meeting prior exercise test at rest standard pulmonary function test, diffusion of CO, TLC and RV will be measured. In addition, Doppler Echocardiography and blood samples for NT-proBNP will be taken prior and post each CPET.
- After 15-20 minute of passive recovery post exercise test all patients will perform 3 short functional tests including 6 minute walk test to assess functional capacity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with severe COPD GOLD stage III- IV, FEV1 30-50% or less of predicted values, greater shortness of breath, reduced exercise capacity, repeated excretions and\ or with chronic respiratory failure [9, 39].
- •IPF patients diagnosed essentially according to the American Thoracic and European Respiratory Societies (ATS-ERS) by clinical diagnostic criteria of: (a) High-resolution computed tomography (HRCT) demonstrating a pattern of "confident" or "possible" IPF (b) Abnormal pulmonary physiology with evidence of restriction and/or impaired gas exchange (can exist during exercise alone) (c) Exclusion of other known causes of interstitial lung disease (e.g.: connective tissue disease, environmental exposure,etc.)[31].
- •Patients post Pneumonectomy more than 6 month from the amputation surgery for any diagnosis (Cancer, Trauma, and Infection- Bronchiectasis).
排除标准
- •Patients with known sensitivity or contraindications to phosphodiesterase 5 (PDE-5) inhibitor therapies will be excluding from the study.
- •Thromboembolic disease will be excluded by pulmonary CT-angiography or perfusion scan.
- •Patients with a history of left-sided heart failure will be excluded.
- •Patients will also exclude if they are on regular treatment with nitrates or PDE-5 inhibitors (Sildenafil, Tadalafil, Vardenafil).
研究组 & 干预措施
Sildenafil
Experimental
干预措施: Sildenafil (Drug)
结局指标
主要结局
VO2 Peak
时间窗: 2-30 days between exercise tests
6 min walk test
时间窗: 2-30 days between exercise tests
Distance walked in 6 min test
Functional Tests
时间窗: 2-30 days between exercise tests
1. 30 seconds chair stand test- number of repetitions in 30 sec 2. 8-ft-up-and -go (agility and coordination)- number of sec that takes to complete the task.
次要结局
- Pulmonary Arterial Pressure(2-30 days between exercise tests)
- NT-pro-BNP(2-30 days between exercise tests)
研究者
Mordechai Kremer
Prof. Mordechai R. Kramer, Head of Pulmonary Institute
Rabin Medical Center
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPDChronic Obstructive Pulmonary DiseaseNCT05061368University of Alberta160
已完成
1 期
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CFCystic FibrosisNCT02626182National Jewish Health14
已完成
3 期
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary FibrosisHypertension, PulmonaryPulmonary FibrosisNCT00517933Duke University180
尚未招募
不适用
Effects of sildenafil on the pulmonary microvascular disease of symptomatic smokerC08.618.326Tobacco usedyspneaZ72.0RBR-9t6rd7niversidade Federal de Mato Grosso do Sul
已完成
2 期
The Impact of Sildenafil on the Pulmonary Circulation in Healthy Trained and Untrained HumansHealthyNCT04985929University of Alberta26